outbreak
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
rapidli
spread
china
countri
govern
medic
commun
take
step
prevent
transmiss
common
sens
recommend
radic
quarantin
measur
context
time
recommend
concern
screen
donor
human
cell
tissu
cellular
tissuebas
product
releas
potenti
transmiss
transplant
yet
known
sever
institut
recommend
interim
precaut
screen
new
donor
us
food
drug
administr
suggest
consid
donor
histori
travel
area
outbreak
cohabit
infect
individu
diagnosi
suspicion
within
day
recoveri
donor
tissu
similar
measur
taken
global
allianc
eye
bank
associ
joint
unit
kingdom
blood
transfus
servic
profession
advisori
committe
rule
potenti
donor
european
societi
blood
marrow
transplant
recommend
exclud
potenti
donor
diagnos
wait
least
day
donat
histori
highrisk
travel
contact
itali
outbreak
spread
rapidli
nation
transplant
centr
taken
stronger
measur
recommend
test
potenti
tissu
stemcel
live
donor
well
dead
donor
realtim
rtpcr
assay
nasopharyng
swab
sampl
bronchoalveolar
lavag
deceas
individu
faecal
microbiota
transplant
novel
treatment
rapidli
earn
major
role
manag
recurr
clostridioid
difficil
infect
clear
advantag
antibiot
becom
increasingli
widespread
standardis
around
world
last
year
intern
expert
panel
includ
sever
author
comment
releas
recommend
screen
faecal
microbiota
transplant
donor
includ
medic
histori
blood
stool
examin
preexist
condit
advanc
liver
diseas
especi
older
patient
comorbid
research
focu
caus
liver
injuri
effect
exist
liverrel
comorbid
treatment
outcom
declar
compet
interest
given
global
outbreak
intern
group
expert
faecal
microbiota
transplant
stool
bank
believ
recommend
updat
least
temporarili
screen
stool
donor
urgent
need
risk
transmit
faecal
microbiota
transplant
might
higher
tissu
transplant
evid
shown
found
faec
stool
sampl
remain
posit
viru
even
longer
detect
respiratori
tract
suggest
possibl
faecalor
rout
transmiss
concept
support
presenc
gastrointestin
symptom
patient
affect
anoth
relev
issu
faecal
microbiota
transplant
classifi
way
worldwid
countri
regul
transplant
drug
eg
usa
uk
franc
tissu
eg
itali
other
provid
specif
regul
eg
australia
discrep
result
confus
scenario
countri
appli
rule
human
cell
tissu
cellular
tissuebas
product
other
potenti
contribut
spread
infect
alarm
issu
repres
uncontrol
practic
homemad
faecal
microbiota
transplant
widespread
among
patient
want
tri
treatment
indic
outsid
clinic
guidelin
clinic
trial
prevent
transmiss
propos
addit
current
donor
screen
measur
countri
donat
physician
screen
two
main
item
presenc
typic
symptom
includ
fever
fatigu
dri
cough
myalgia
dyspnoea
headach
within
previou
day
donor
histori
travel
region
known
affect
close
contact
individu
proven
suspect
infect
within
previou
day
either
item
posit
potenti
donor
either
reject
test
rtpcr
assay
endem
countri
rtpcr
assay
consid
donor
even
asymptomat
histori
highrisk
travel
contact
altern
donor
stool
store
quarantin
day
use
releas
donor
develop
symptom
final
stool
bank
retrospect
check
health
statu
donor
use
frozen
faec
accord
local
epidemiolog
avoid
potenti
spread
suggest
tailor
local
healthcar
organis
updat
accordingli
insight
gain
patient
encount
earli
experi
use
faecal
bacteriotherapi
treat
recurr
clostridioid
difficil
infect
includ
woman
admit
hospit
six
time
sever
complic
infect
toddler
antibiot
half
life
relentless
sever
diarrhoea
weight
loss
due
recurr
c
difficil
infect
cure
singl
dose
stool
donat
famili
member
procedur
known
faecal
microbiota
transplant
fmt
previous
consid
last
resort
practic
fmt
greatli
increas
sinc
first
randomis
control
trial
rct
publish
strong
consensu
among
doctor
procedur
fmt
effect
option
recurr
c
difficil
infect
nevertheless
placebocontrol
fmt
trial
design
show
efficaci
safeti
recurr
c
difficil
infect
ongo
place
enrol
patient
risk
recurr
vast
clinic
experi
exist
data
confirm
superior
fmt
antibiot
prevent
recurr
c
difficil
infect
adult
placebocontrol
trial
fmt
meet
requir
clinic
equipoisei
genuin
uncertainti
one
treatment
superior
anoth
given
lack
equipois
high
efficaci
fmt
substanti
morbid
mortal
associ
recurr
c
difficil
infect
placebo
arm
still
use
trial
fmt
indic
although
consid
rigor
mean
analys
effect
intervent
placebocontrol
trial
must
balanc
valu
adher
scientif
method
also
protect
research
particip
potenti
ethic
concern
intern
accept
guidelin
support
use
placebo
specif
circumst
proven
effect
treatment
condit
studi
withhold
treatment
pose
neglig
risk
patient
compel
methodolog
reason
use
placebo
trial
requir
particip
forgo
treatment
would
otherwis
receiv
none
criteria
appli
treatment
recurr
c
difficil
infect
fmt
metaanalys
rct
investig
fmt
prevent
recurr
c
difficil
infect
standard
antibiot
treatment
show
high
efficaci
number
need
treat
three
fact
thousand
patient
treat
essenti
serv
control
fail
multipl
antibiot
cours
includ
taper
regimen
drawn
month
achiev
longterm
cure
fmt
healthi
donor
furthermor
microbiom
analys
shown
dramat
resolut
dysbiosi
recipi
suggest
mechan
therapeut
effect
fmt
strongli
recommend
expert
treatment
guidelin
rapidli
becom
standard
care
patient
come
us
hopeless
debilit
receiv
endless
cycl
antibiot
cours
recurr
c
difficil
infect
describ
live
hold
miss
school
work
becom
social
isol
spend
thousand
dollar
treatment
consum
anxieti
possibl
episod
mere
caus
diarrhoea
c
difficil
infect
fatal
mortal
hospitalis
patient
high
nearli
american
per
year
die
within
day
diagnosi
c
difficil
infect
withhold
fmt
patient
result
seriou
harm
death
therefor
placebo
role
first
rct
fmt
stop
earli
high
recurr
rate
control
group
search
clinicaltri
gov
use
search
term
fmt
c
difficil
list
